Lucas Moreno MD, PhD
Dr. Lucas Moreno leads the Clinical Trials Unit at FIBHNJ and has devoted his career to childhood cancer drug development. He is funded by a highly competitive mid-career national government fellowship (Juan Rodés) and is dedicated to early clinical trials in paediatric cancers, with interest in neuroblastoma and biomarker development.
In April 2013, he created the CNIO-HNJ Clinical Research Unit for Paediatric Phase I/II Trials, that focuses in the design and development of first-in-child phase I trials and early clinical trials of molecularly targeted agents and immunotherapeutics. In 4 years, the number of open clinical trials have increased four-fold, from 9 to 35, including 8-first-in-child clinical studies of targeted agents. The Unit currently provides service for early clinical trials in Paediatric Oncology, Haematology, Stem Cell Transplantation and Supportive care and is expanding its portfolio to other Paediatric Specialties.
He is a key opinion leader in neuroblastoma drug development in Europe, chairs the Drug Development group and is member of the Executive Committee of the European Neuroblastoma Network (SIOPEN) and is member of the Clinical Trials Committee of the ITCC consortium. He is the international Chief Investigator of the randomised phase 2 trial BEACON-neuroblastoma open in 10 European countries for relapsed & refractory neuroblastoma. He has led the development of pharmacodynamic biomarkers for PI3K inhibitors in neuroblastoma which are now ready to be implemented in early clinical trials. He is also invited investigator at the Spanish National Cancer Research Centre (CNIO) and is running several projects in neuroblastoma drug development.
He is ANECA accredited as "Profesor Contratado Doctor" and author of 45 international publications in peer-reviewed journals in the field of drug development and paediatric cancers.